Asset
PONESIMOD
Vanda Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07362017 | phase3 | recruiting | 2026-02-17 | 2028-08-01 | Vanda Pharmaceuticals | Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis |
| NCT07686081 | phase3 | recruiting | 2026-09-01 | 2029-04-01 | Vanda Pharmaceuticals | Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 213498 | NDA | VANDA PHARMACEUTICALS INC |
Marketed products (10)
- PONVORY
- PONVORY
- PONVORY
- PONVORY
- PONVORY
- PONVORY
- PONVORY
- PONVORY
- PONVORY
- PONVORY